Literature DB >> 28785134

Type 2 Minocycline-induced hyperpigmentation successfully treated with the novel 755 nm picosecond alexandrite laser - a case report.

Katsumi Sasaki1, Toshio Ohshiro2, Takafumi Ohshiro1, Reiko Sakio1, Emi Fukazawa3, Masahiro Toriumi3, Tamotsu Ebihara4.   

Abstract

BACKGROUND AND AIM: Minocycline therapy for acne vulgaris is associated with the occasional induction of various types of unsightly and often persistent hyperpigmentation, which is frequently resistant to hydroquinone treatment. Pigment-specific lasers have achieved some success with multiple treatment sessions. Recently, the picosecond domain 755 nm alexandrite laser (ps-Alex) has attracted attention in tattoo removal. The present study reports on the successful treatment, in a single ps-Alex session, of minocycline-associated pigmentation. SUBJECT AND
METHOD: Subsequent to a course of minocycline, a 28-year-old Asian female developed persistent type 2 minocycline-related pigmentation on the bilateral lower extremities which was recalcitrant to hydroquinone treatment. The patient had a test treatment on a small area with a Q-switched ruby laser and the ps-Alex, following which the ps-Alex was selected for the actual treatment (spot size, 2 mm; fluence, 6.37 J/cm2; pulsewidth, 750 ps) on one leg first, followed later by the contralateral leg.
RESULTS: Rapid clearance of the pigmentation was noted after a single ps-Alex session on both limbs without prolonged post-inflammatory hyperpigmentation (PIH). At one year post-treatment, clearance had been maintained.
CONCLUSIONS: Our results in this single case strongly suggest that the novel 755-nm ps-Alex laser is both safe and very effective for the treatment of type 2 minocycline-induced hyperpigmentation even in PIH-prone type IV Asian skin. Further trials with larger patient populations are warranted to confirm this optimistic result.

Entities:  

Keywords:  Asian skin; Minocycline; picosecond alexandrite laser; postinflammatory hyperpigmentation; type 2 minocycline-induced pigmentation

Year:  2017        PMID: 28785134      PMCID: PMC5539381          DOI: 10.5978/islsm.17-CR-03

Source DB:  PubMed          Journal:  Laser Ther        ISSN: 0898-5901


  12 in total

1.  A retrospective analysis on the management of pigmented lesions using a picosecond 755-nm alexandrite laser in Asians.

Authors:  Johnny Chun-yin Chan; Samantha Yee-nam Shek; Taro Kono; Chi Keung Yeung; Henry Hin-lee Chan
Journal:  Lasers Surg Med       Date:  2015-12-22       Impact factor: 4.025

2.  Q-switched ruby laser treatment of minocycline-induced cutaneous hyperpigmentation.

Authors:  K A Knoell; S S Milgraum; M Kutenplon
Journal:  Arch Dermatol       Date:  1996-10

3.  Successful and rapid treatment of blue and green tattoo pigment with a novel picosecond laser.

Authors:  Jeremy A Brauer; Kavitha K Reddy; Robert Anolik; Elliot T Weiss; Julie K Karen; Elizabeth K Hale; Lori A Brightman; Leonard Bernstein; Roy G Geronemus
Journal:  Arch Dermatol       Date:  2012-07

4.  Treatment of pigmentary disorders in patients with skin of color with a novel 755 nm picosecond, Q-switched ruby, and Q-switched Nd:YAG nanosecond lasers: A retrospective photographic review.

Authors:  Melissa Kanchanapoomi Levin; Elise Ng; Yoon-Soo Cindy Bae; Jeremy A Brauer; Roy G Geronemus
Journal:  Lasers Surg Med       Date:  2016-02       Impact factor: 4.025

5.  Complete resolution of minocycline pigmentation following a single treatment with non-ablative 1550-nm fractional resurfacing in combination with the 755-nm Q-switched alexandrite laser.

Authors:  Ramya K Vangipuram; Whitney L DeLozier; Elizabeth Geddes; Paul M Friedman
Journal:  Lasers Surg Med       Date:  2015-12-30       Impact factor: 4.025

6.  Picosecond pulse duration laser treatment for dermal melanocytosis in Asians : A retrospective review.

Authors:  Takafumi Ohshiro; Toshio Ohshiro; Katsumi Sasaki; Kazuo Kishi
Journal:  Laser Ther       Date:  2016-06-29

Review 7.  Minocycline-induced skin pigmentation: an update.

Authors:  Aanand N Geria; Ani L Tajirian; George Kihiczak; Robert A Schwartz
Journal:  Acta Dermatovenerol Croat       Date:  2009       Impact factor: 1.256

8.  Minocycline-induced hyperpigmentation treated with a 755-nm Q-switched alexandrite laser.

Authors:  Tina S Alster; Samir N Gupta
Journal:  Dermatol Surg       Date:  2004-09       Impact factor: 3.398

9.  Treatment of tattoos with a picosecond alexandrite laser: a prospective trial.

Authors:  Nazanin Saedi; Andrei Metelitsa; Kathleen Petrell; Kenneth A Arndt; Jeffrey S Dover
Journal:  Arch Dermatol       Date:  2012-12

10.  The histopathology of subcutaneous minocycline pigmentation.

Authors:  Anneli Ririe Bowen; Timothy H McCalmont
Journal:  J Am Acad Dermatol       Date:  2007-11       Impact factor: 11.527

View more
  5 in total

1.  A Severe Case of Minocycline-induced Hyperpigmentation of the Lower Extremities.

Authors:  Eric D Schadler; Thomas L Cibull; Stephanie L Mehlis
Journal:  Cureus       Date:  2018-05-22

2.  Severe Type of Minocycline-Induced Hyperpigmentation Mimicking Peripheral Arterial Occlusive Disease in a Bullous Pemphigoid Patient.

Authors:  Meng-Yu Wu; Yueh-Tseng Hou; Giou-Teng Yiang; Andy Po-Yi Tsai; Ching-Hsiang Lin
Journal:  Antibiotics (Basel)       Date:  2019-07-16

3.  Insight into the mechanisms of type III minocycline-induced pigmentation removal: A case of repeated immediate pigment clearing with the Q-switched 755-nm alexandrite laser over a 13-year period.

Authors:  Tiffany Y Loh; Matthew S Goldberg; Ryan R Falsey; Jennifer K Barton; Paul Sagerman; Gerald N Goldberg
Journal:  JAAD Case Rep       Date:  2019-09-24

4.  755-nm Alexandrite Picosecond Laser with a Diffractive Lens Array or Zoom Handpiece for Post-Inflammatory Hyperpigmentation: Two Case Reports with a Three-Year Follow-Up.

Authors:  Rongxin Ren; Shiwei Bao; Wenjiang Qian; Hongyi Zhao
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-10-12

5.  Treatment of Laser-Responsive Dermal Pigmentary Conditions in Type III-IV Asian Skin With a 755-nm Picosecond Pulse Duration Laser: A Retrospective Review of Its Efficacy and Safety.

Authors:  Yun Pei Koh; Aaron Wei Min Tan; Sze Hon Chua
Journal:  Dermatol Surg       Date:  2020-11       Impact factor: 2.914

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.